Adma Biologics (ADMA) Accounts Payables (2011 - 2025)

Adma Biologics' Accounts Payables history runs 14 years deep, the most recent figure standing at $22.5 million for Q4 2025.

• Quarterly Accounts Payables rose 11.38% year-over-year to $22.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.5 million (up 11.38% YoY) and the FY2025 annual result came in at $22.5 million, up 11.38% from the prior year.
• Accounts Payables was $22.5 million for Q4 2025 at Adma Biologics, down from $24.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $29.8 million in Q2 2025 and bottomed at $6.2 million in Q2 2021.
• A 5-year average of $16.4 million and a median of $14.9 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables soared 116.58% — and 2023, when it tumbled 56.93%.
• Adma Biologics' Accounts Payables stood at $12.4 million in 2021, then gained by 6.43% to $13.2 million in 2022, then gained by 18.38% to $15.7 million in 2023, then climbed by 29.11% to $20.2 million in 2024, then gained by 11.38% to $22.5 million in 2025.
• Business Quant data shows ADMA's Accounts Payables at $22.5 million in Q4 2025, $24.0 million in Q3 2025, and $29.8 million in Q2 2025.